

March 4, 2020



Code: 532 321

Listing Department

BSE LIMITED

P J Towers, Dalal Street, Fort,

Mumbai - 400 001

Listing Department

Code: CADILAHC

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai <u>– 400 051</u>

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated March 4, 2020 titled "Zydus receives final approval from the USFDA for Emtricitabine and Tenofovir disoproxil Fumarate Tablets 200 mg / 300 mg".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above





Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Zydus receives final approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg

The company also receives tentative approval for 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg of the same drug.

Ahmedabad, 4, March, 2020

Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg (US RLD: Truvada® Tablets) and tentative approval for the strengths of 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg, of the same drug.

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in the body so the immune system can work better. This will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 281 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

CIN: L24230GJ1995PLC025878